Compare RHI & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RHI | ACAD |
|---|---|---|
| Founded | 1948 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 4.3B |
| IPO Year | 1994 | 2000 |
| Metric | RHI | ACAD |
|---|---|---|
| Price | $42.49 | $27.94 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 22 |
| Target Price | $30.33 | ★ $30.55 |
| AVG Volume (30 Days) | ★ 1.6M | 1.4M |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | ★ 8.68% | N/A |
| EPS Growth | N/A | ★ 69.12 |
| EPS | ★ 0.40 | 0.20 |
| Revenue | ★ $5,378,506,000.00 | $726,437,000.00 |
| Revenue This Year | $1.27 | $18.80 |
| Revenue Next Year | $5.95 | $11.70 |
| P/E Ratio | ★ $107.00 | $141.35 |
| Revenue Growth | N/A | ★ 40.45 |
| 52 Week Low | $21.83 | $19.69 |
| 52 Week High | $46.70 | $30.96 |
| Indicator | RHI | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 51.96 | 48.65 |
| Support Level | $26.19 | $27.90 |
| Resistance Level | $46.70 | $30.96 |
| Average True Range (ATR) | 1.44 | 0.84 |
| MACD | -0.44 | -0.29 |
| Stochastic Oscillator | 13.72 | 2.18 |
Robert Half Inc was founded in 1948, Robert Half provides temporary, permanent, and outcome-based staffing for both in-person and remote positions in the finance and accounting, technology, legal, marketing, and administrative fields. Its subsidiary consulting arm, Protiviti, specializes in technology, risk, auditing, and compliance matters. The firm generates its sales inside the U.S. and is one of the specialized firms in the fragmented U.S. staffing industry.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.